ArticleHIV medicine2025
Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World Study.Open forum infectious diseases · 2026Trial
- TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry.Cell communication and signaling : CCS · 2026Review
- Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV Prevention.Clinical pharmacology : advances and applications · 2026Review
- Natural occurrence of drug resistance mutations to the HIV-1 capsid inhibitor lenacapavir.HIV medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsLenacapavir (LEN) is a first-in-class HIV-1 capsid inhibitor. We investigated the natural occurrence of LEN drug resistance mutations (DRM) in HIV-1 sequences from LEN treatment-naïve individuals.
methodsWe analysed all available HIV-1 capsid sequences (n = 21 646) from individuals never exposed to LEN from the Los Alamos National Laboratory database.
resultsLEN DRMs were identified at all LEN DRM-associated positions, including the highly resistant M66I variant, which was found in 9 sequences across multiple subtypes. In total, 56 sequences (0.26%) contained LEN DRMs. The most prevalent mutation was Q67H (n = 22), and this mutation was more common in CRF01_AE (17/3053, 0.56%).
conclusionsAll known LEN DRMs can be found in viral populations without drug pressure. This finding may reflect immunological pressure on capsid epitopes containing DRMs. Our findings are of potential clinical relevance for LEN use in both therapeutic and prophylactic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.